MELVILLE, N.Y. – Nikon Instruments Inc., a subsidiary of Nikon Corporation (7731), announced today a strategic partnership with Yamaha Motor Co., Ltd. to enhance drug discovery research support services in the United States. Nikon shares have shown strong momentum with a 30% gain over the past six months, according to InvestingPro data.

Under the agreement, Nikon’s BioImaging Lab (NBIL) in greater Boston will host Yamaha’s CELL HANDLER 2, a cell picking and imaging system launched by Yamaha in March 2025.

The collaboration aims to integrate Nikon’s advanced imaging technologies with Yamaha’s cell handling capabilities to provide specialized support for researchers working in pharmaceutical development and related fields.

Researchers considering purchasing the CELL HANDLER 2 system will be able to conduct verification tests with their own samples at the Boston facility, allowing them to confirm the system’s effectiveness and develop customized assay workflows for their specific research requirements.

The partnership seeks to expand the adoption of both Nikon’s cellular observation technologies and Yamaha’s cell handling system, which is designed to streamline research workflows in drug development.

Nikon Instruments operates as a wholly owned U.S. subsidiary of Nikon Corporation, focusing on optical and digital imaging technologies for biomedical applications. The company established its BioImaging Lab subsidiary in 2019 to provide specialized microscope imaging and image analysis support.

The announcement, based on a company press release, represents a cross-industry collaboration between two Japanese manufacturers bringing complementary technologies to the U.S. biomedical research market.